Compare MYRG & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYRG | IDYA |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | MYRG | IDYA |
|---|---|---|
| Price | $211.30 | $33.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $214.14 | $49.42 |
| AVG Volume (30 Days) | 273.0K | ★ 908.2K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 169.25 | N/A |
| EPS | ★ 6.17 | N/A |
| Revenue | ★ $3,514,140,000.00 | $214,834,000.00 |
| Revenue This Year | $8.62 | $2,434.86 |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $35.36 | ★ N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $97.72 | $13.45 |
| 52 Week High | $241.13 | $37.08 |
| Indicator | MYRG | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 50.36 |
| Support Level | $209.38 | $33.10 |
| Resistance Level | $230.12 | $34.45 |
| Average True Range (ATR) | 9.74 | 1.39 |
| MACD | -1.45 | -0.35 |
| Stochastic Oscillator | 5.17 | 9.55 |
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution networks and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.